Clinical Trials Appendix

Q4 2024 Results Update

February 27, 2025

Disclosures

Certain statements contained in this presentation and in any accompanying oral presentation, other than statements of fact that are independently verifiable at the date hereof, may constitute forward-looking statements. Examples of such forward-looking statements include statements regarding the projected dates for upcoming regulatory approvals; and BeiGene's research, discovery, and pre-clinical and early-stage clinical programs and plans. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and medicines; BeiGene's reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeiGene's limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeiGene's ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled "Risk Factors" in BeiGene's most recent periodic report filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the SEC. All information in this presentation is as of the date of this presentation, and BeiGene undertakes no duty to update such information unless required by law.

Our Pipeline Snapshot

Across three therapy areas:





150+

Clinical studies run by BeiGene

40+

Clinical and commercial stage assets

24,000+

Patients enrolled in clinical trials globally*

70+

Approvals for BRUKINSA® (zanubrutinib) globally

*Includes investigator initiated trials (IITs)

BeiGene: Upcoming Regulatory Action Catalysts 1H 2025 – 1H 2026

Potential Approvals



1H, 2025

Q1

TEVIMBRA – 302 2L ESCC **JP**

TEVIMBRA – 306 1L ESCC **US*, JP**

Q2

BRUKINSA – additional ~12 global approvals

TEVIMBRA – 305 1L GC **AU**

TEVIMBRA – 302 2L ESCC **US** Alt Dosing Q2/4W

TEVIMBRA – additional ~5 global approvals

2H, 2025

BRUKINSA – 114 Tablet formulation **US, EU, AU**

BRUKINSA – additional ~10 global approvals

TEVIMBRA – 305 1L GC **BR, UK**

TEVIMBRA – 306 1L ESCC **BR, UK**

TEVIMBRA – 309 1L NPC **AU, CA, EU**

TEVIMBRA – 312 1L ES-SCLC **EU**

TEVIMBRA – 315 Neo/adj NSCLC **EU**

TEVIMBRA – Alt Dosing Q2/4/6W **US, AU** (Q2/4W)

TEVIMBRA – additional ~45 global approvals

1H, 2026

BRUKINSA – 114 Tablet formulation **UK**

BRUKINSA – additional ~5 global approvals

TEVIMBRA – 302 2L ESCC **CA**

TEVIMBRA – 304 IL Non Sq NSCLC **BR**

TEVIMBRA – 305 1L GC **CA**

TEVIMBRA – 306 2L ESCC **CA**

TEVIMBRA – 307 IL Sq NSCLC **BR**

TEVIMBRA – 309 1L NPC **UK**

TEVIMBRA – 312 1L ES-SCLC **UK**

TEVIMBRA – 315 Neo/adj NSCLC **UK**

TEVIMBRA – Alt Dosing Q6W **EU, CN**

TEVIMBRA – additional ~18 global approvals

* Due to a delay in scheduling clinical inspections, the target PDUFA date of July 2024 was deferred

BR - Brazil; CN - China; AU – Australia; JP - Japan; UK – United Kingdom; CA – Canada; EU – European Union

Refer to Glossary for other abbreviations

BeiGene: Project Movements Since Q3 2024 Update

New to Phase 1/1b

BG-60366-101 (EGFR-CDAC)

BG-89894 (MAT2Ai)*

BG-C477-101 (CEA ADC)

BG-T187-101 (EGFRxMET)

BGB-53038-101 (Pan-KRASi)

BG-C137-101 (FGFR2b ADC)

BGB-21447-102 (BCL2i 2G)

BGB-B455-101 (Claudin6xCD3)

New to Phase II

New to Pivotal Trial

BGB-11417-302 (BCL2i)

New Submission[1]

Zanubrutinib 114 (tablet) in US, CH, AU

Zanubrutinib 212 (R/R FL) in IL, MX, SA

Zanubrutinib 304, 305 (R/R & TN CLL, CLL PFS, WM) in TR; (CLL PFS update) in UY, SA, MX

Zanubrutinib 214 (R/R MZL) in MY

Tislelizumab 302 (2L ESCC) in PH, SA, TW

Tislelizumab 305 (1L GC) in HK, IL, MO, PH, SA

Tislelizumab 306 (1L ESCC) in HK, PH, SA, UK

Tislelizumab 303, 304, 307 (1L/2L NSCLC) in HK, MO, PH, TW, SA

Tislelizumab 309 (1L NPC) in EU, KR, SG

Tislelizumab 312 (ES-SCLC) in EU, IS, NO

Tislelizumab 315 (Neo/adj NSCLC) in EU, IS, NO

Tislelizumab- Alt Dosing Q4W 2L ESCC in US; **Q2/4W** in AU; **Q6W** in CN

Approved

Zanubrutinib 212 (R/R FL) in IL, SG

Zanubrutinib 206

(R/R MCL) in UK

Zanubrutinib 304, 305

(R/R & TN CLL) in JP, RU; (PFS update) in EC, SG, RU

Zanubrutinib 114 (tablet) in CA

Tislelizumab 302 (2L ESCC) in HK, ID, MY, NZ

Tislelizumab 305 (1L GC) in EU, IS, LI, NO, MO, US

Tislelizumab 306 (1L ESCC) in AU, EU, IS, LI, NO

Tislelizumab 303, 304, 307 (1L/2L NSCLC) in ID, NZ, UK

Tislelizumab 303, 307 (1L sq/2L NSCLC) in IL

Tislelizumab 312 (1L ES-SCLC) in MO

Tislelizumab 315 Neo adj/adj NSCLC in CN

AR - Argentina; AU – Australia; BR - Brazil; CA – Canada; CH – Switzerland; CN - China; EC – Ecuador; HK – Hong Kong; ID – Indonesia; IL - Israel; IN - India; IS - Iceland; JP – Japan; KR – South Korea; LI - Liechtenstein; MO – Macao; MX – Mexico; MY – Malaysia; NO - Norway; PH – Philippines; RS – Serbia; RU – Russia; SA – Saudi Arabia; SG - Singapore; TH – Thailand; TR – Turkey; UK – United Kingdom; US – United States; UY – Uruguay; NZ – New Zealand; TW – Taiwan

- In licensed from CSPC

BeiGene → BeOne

Global Clinical Development Pipeline

Updated: 26 February 2025

Phase 1

Sonrotoclax — BCL2i
- 101 B-cell malignancies
- 102 B-cell malignancies
- 103 AML/MDS
- 105 MM t(11;14)
- 108 Dose ramp-up

BGB-43395 — CDK4i
- 101/102 BC & Solid tumors

BGB-53038 — PanKRASi
- 101 Solid tumors

BG-C9074[1] — B7H4 ADC
- 101 Solid tumors

BG-60366 — EGFR CDAC
- 101 Solid tumors

BG-58067 — MTA Coop. PRMT5i
- 101 Solid tumors

BG-89894[2] — MAT2Ai
- 101 Solid tumors

BGB-45035 — IRAK4 CDAC
- 101 Immunology & Inflammation

BG-68501[3] — CDK2i
- 101 BC & Solid tumors

BG-C354 — B7H3 ADC
- 101 Solid tumors

BG-C477 — CEA ADC
- 101 Solid tumors

BG-C137 — FGFR2b ADC
- 101 Solid tumors

BG-T187 — EGFR x MET TsAb
- 101 Solid tumors

BGB-16673 — BTK CDAC
- 101 B-cell malignancies
- 102 B-cell malignancies
- 104 B-cell malignancies

BGB-21447 — BCL2i 2G
- 101 B-cell malignancies
- 102 Metastatic breast cancer

Xaluritamig[4] — STEAP1 x CD3 XmAb®
- 20180146 mCRPC

BGB-R046 — IL-15 prodrug
- 101 Solid tumors

BGB-B2033 — GPC3 x 4-1BB BsAb
- 101 Solid tumors

BGB-B3227 — MUC1 x CD16A BsAb
- 101 Solid tumors

BGB-15025 — HPK1i
- 101 Solid tumors

BGB-26808 — HPK1i
- 101 Solid tumors

BGB-30813 — DGKζi
- 101 Solid tumors

BGB-A3055 — CCR8 mAb
- 101 Solid tumors

BGB-24714 — SMAC mimetic
- 101 Solid tumors

Tislelizumab — PD1 mAb
- 103 SubQ formulation

BGB-B455 — CLDN6 x CD3 BsAb
- 101 Solid tumors†

Phase 2

Zanubrutinib — BTKi
- 215 B-cell malignancies
- 218 CD79B R/R DLBCL

BGB-16673 — BTK CDAC
- 101 R/R CLL
- 102 R/R CLL

Sonrotoclax — BCL2i
- 201 R/R MCL
- 202 R/R CLL
- 203 R/R WM
- 204 TN CLL/SLL

Blinatumomab[4] — CD3 x CD19 BiTE®
- 20190359 Pediatric R/R BP-ALL

LBL-007[5] — LAG3 mAb
- 201 MSS-CRC
- 202 1L ESCC

BGB-A445 — OX40 mAb
- 201 Melanoma, UC

Umbrella Studies — IO Combos
- LC-201 1L NSCLC
- LC-202 Neoadj NSCLC
- HNSCC-201 1L HNSCC

Tarlatamab[4] — DLL3 x CD3 BiTE®
- 20230273 3L SCLC

Phase 3

Zanubrutinib — BTKi
- 306 TN MCL
- 308 R/R MZL, R/R FL
- 309 pMN

Sonrotoclax — BCL2i
- 301 TN CLL
- 302 R/R MCL†

Tislelizumab — PD1 mAb
- 310 1L UBC
- 314 R/R cHL

Pamiparib — PARPi
- 302 2L MTx gBRCAm PSOC

Ociperlimab — TIGIT mAb
- 302 1L NSCLC PDL1-high

Zanidatamab[6] — HER2 BsAb
- 301 1L HER2+ GEA

Tarlatamab[4] — DLL3 x CD3 BiTE®
- 20210004 2L SCLC
- 20200041 1L ES-SCLC
- 20230016 LS-SCLC

Registration

Zanubrutinib — BTKi
- 114 Tablet formulation (US, EU, Others)

Tislelizumab — PD1 mAb
- 312 1L ES-SCLC (EU)
- 315 Neo/adj NSCLC (EU)
- 306 1L ESCC (US, JP)
- 302 2L ESCC (JP)
- 302 2L ESCC alt dosing (US)
- 309 1L NPC (EU)

Zanidatamab[6] — HER2 BsAb
- 203 HER2+ 2L BTC (CN)

Heme · Breast / Gyn · Pan-Tumor / Other · Lung · GI · Non-Oncology

Registration includes select accepted submissions in major markets.
† Trial is listed on clinicaltrials.gov but may not have subjects enrolled.
1) DualityBio collaboration, 2) CSPC collaboration, 3) Ensem collaboration, 4) Amgen collaboration, 5) Leads Biolabs collaboration, 6) Zymeworks/Jazz collaboration.
Please refer to our most recent 10-K filing for a full list of our commercial products, including in-licensed products, as well as commercial rights and collaboration details

BeiGene → BeOne

12 Innovative Solid Tumor NMEs Entered the Clinic In 2024 In Priority Tumor Types with Diverse Modalities and Mechanisms

Lung

- PanKRASi
- MTA Cooperative PRMT5i
- MAT2Ai
- CEA ADC
- B7H3 ADC
- EGFR CDAC
- EGFR x MET Tsp

Breast/Gynecologic

- CDK4i
- CDK2i
- BCL2i 2G
- KAT6A/B*
- B7H4 ADC
- Claudin6 x CD3

GI

- PanKRASi
- MTA Cooperative PRMT5i
- MAT2Ai
- FGFR2b ADC
- CEA ADC
- GPC3 x 4-1BB
- MUC1 x CD16A

Pan-Tumor

- DGKζi
- HPK1i
- SMAC Mimetic
- CCR8
- IL-15 prodrug

Small molecule | Protein degrader | Bi/Tri-specific | mAb | ADC | Cytokine therapy

BeiGene has global rights for CDK2 (Ensem partnership), B7H4 ADC (DualityBio partnership), MAT2A (CSPC Zhongqi Pharmaceutical Technology); * Not yet in the clinic

BeiGene: Building Leadership in Solid Tumors with Innovative NMEs

	Phase 1			Phase 2			Phase 3	
Breast/ Gynecologic Cancers	**BGB-C9074-101** **B7H4-ADC** Breast (other ST)	**BGB-43395-101/102** **CDK4i** Breast (other ST)	**BGB-21447*** **BCL2i 2G** HR+ BC					
	BG-68501-101 CDK2i Breast (other ST)	**BGB-24714-101** **SMAC** Solid Tumors	**BGB-B455** **Claudin6xCD3** Gyn (other ST) †					
Gastro-intestinal		**BGB-B2033-101** **GPC3x4-1BB** Solid Tumors	**BG-C137-101** **FGFR2b ADC** GI	**BGB-LBL-007-201** **LAG-3** MSS-CRC	**BGB-LBL-007-202** **LAG-3** 1L ESCC		**ZWI-ZW25-301** **Zanidatamab HER2** 1L HER2+ GEA	
	BG-53038-101 **Pan-KRASi** GI and lung	**BG-C477-101** **CEA ADC** GI and Lung	**BGB-B3227-101** **MUC1xCD16A** Lung and GI					
Lung	**AMG757 20230298** **Tarlatamab DLL3xCD3** 2L+ SCLC (CN)	**BGB-C354-101** **B7H3 ADC** Lung, GI and HNSCC	**BG-T187** **EGFRxMET Tsp** Lung and GI	**BGB-LC-201** **Umbrella** 1L NSCLC	**BGB-LC-202** **Umbrella** Neoadjuvant NSCLC	**AMG757 20230273** **Tarlatamab DLL3xCD3** 3L SCLC (CN)	**AdvanTIG-302** **Ociperlimab TIGIT** 1L NSCLC (PDL1 high)	**AMG757 20200041** **Tarlatamab DLL3xCD3** 1L ES-SCLC (CN)
	BG-60366-101 **EGFR-CDAC** Lung	**BGB-58067-101** **MTA-coop PRMT5i** Lung and GI	**BG-89894** **MAT2Ai** Lung and GI				**AMG757 20210004** **Tarlatamab DLL3xCD3** 2L SCLC (CN)	**AMG757 20230016** **Tarlatamab DLL3xCD3** LS-SCLC (CN)
Pan-tumor /Other	**BGB-30813-101** **DGKζ** Solid Tumors	**BGB-A3055-101** **CCR8** Solid Tumors	**BGB-R046-101** **Pro-IL15** Solid Tumors	**BGB-HNSCC-201** **Umbrella** 1L HNSCC	**BGB-A317-A445-201** **BGB-A445 OX40** Melanoma and UC			
	BGB-15025-101 **HPK1** Solid Tumors	**BGB-26808-101** **HPK1 2G** Solid Tumors	**AMG509 20180146** **XaluritamigSTEAP1xCD3** mCRPC (CN)					

Refer to Glossary abbreviations

* Additionally, in Ph1 in Heme indications.

† Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

BeiGene: Building Leadership in Solid Tumors With LCM

	Phase 1	Phase 2	Phase 3	Approved		
Breast/ Gynecologic Cancers			**BGB-290-302** **Pamiparib PARPi** 2L+ MTx OC	**BGB-290-102** **Pamiparib PARPi** 2L+ gBRCAm OC	**Baituowei (Goserelin)** Breast, Prostate	
Gastro-intestinal		**BGB-A317-209** **Tislelizumab PD-1** Resect MSI-H/ dMMR CRC		**BGB-A317-301** **Tislelizumab PD-1** 1L HCC	**BGB-A317-302** **Tislelizumab PD-1** 2L ESCC	**BGB-A317-305** **Tislelizumab PD-1** 1L GC
				BGB-A317-306 **Tislelizumab PD-1** 1L ESCC	**BGB-A317-208** **Tislelizumab PD-1** 2L/3L+HCC	
Lung				**BGB-A317-304** **Tislelizumab PD-1** 1L Non-sq. NSCLC	**BGB-A317-307** **Tislelizumab PD-1** 1L Sq. NSCLC	**BGB-A317-303** **Tislelizumab PD-1** 2/3L NSCLC
				BGB-A317-312 **Tislelizumab PD-1** 1L ES-SCLC	**BGB-A317-309** **Tislelizumab PD-1** 1L NPC	**BGB-A317-315** **Tislelizumab PD-1** Neo-adj./adj. NSCLC
Pan tumor /Other	**BGB-A317-103** **Tislelizumab PD-1** Subcutaneous		**BGB-A317-310** **Tislelizumab PD-1** 1L UBC	**BGB-A317-204** **Tislelizumab PD-1** 2L UC	**BGB-A317-209** **Tislelizumab PD-1** Late Line MSI-H or dMMR	
			BGB-A317-290-LTE1 **Multiple BeiGene assets** LTE Solid Tumors			

Refer to Glossary abbreviations

BeiGene: a Leader in Hematology / I&I portfolio – Innovative NMEs

	Phase 1	Phase 2	Phase 3
AML/MDS, Multiple Myeloma, Other Heme	**BGB-11417-103** Sonrotoclax BCL2i AML/MDS **BGB-11417-105** Sonrotoclax BCL2i Multiple Myeloma t(11;14)		
B-Cell	**BGB-21447-101** BCL2i 2G B-Cell Malignancies **BGB-11417-102** Sonrotoclax BCL2i B-Cell Malig.(China) **BGB-11417-101** Sonrotoclax BCL2i mono & combo w/ zanu **BGB-16673-101** BTK CDAC B-Cell Malig. **BGB-16673-102** BTK CDAC B-Cell Malig. (China) **BGB-16673-104** BTK CDAC B-Cell Malig. combos	**BGB-11417-201** Sonrotoclax BCL2i R/R MCL **BGB-11417-202** Sonrotoclax BCL2i CLL/SLL (China) **BGB-11417-203** Sonrotoclax BCL2i R/R WM **BGB-11417-204** Sonrotoclax BCL2i TN CLL **BGB-16673-101/102** BTK CDAC R/R MCL & R/R CLL	**BGB-11417-301** Sonrotoclax BCL2i TN CLL combo + zanu **BGB-11417-302** Sonrotoclax BCL2i R/R MCL
I&I	**BGB-45035-101** IRAK4 CDAC Healthy volunteers		

Refer to Glossary abbreviations

BeiGene: a Leader in Hematology / I&I With LCM

	Phase 1	Phase 2	Phase 3	Approved
AML/MDS, Multiple Myeloma, Other Heme		**BLINCYTO® CD3/CD19 BiTE** Pediatric R/R BP-ALL	**BGB-A317-314 Tislelizumab PD-1** R/R cHL (China)	**BGB-A317-203 Tislelizumab PD-1** R/R cHL
B-Cell		**BGB-3111-215 Zanubrutinib BTKi** Prev. BTKi Tx intolerant **BGB-3111-111 Zanubrutinib BTKi** R/R CLL/SLL, WM, MCL (JP) **BGB-3111-218 Zanubrutinib BTKi** CD79B R/R DLBCL **BGB-3111-304 Zanubrutinib BTKi** TN CLL Ven combo	**BGB-3111-306 Zanubrutinib BTKi** TN MCL **BGB-3111-308 Zanubrutinib BTKi** R/R MZL, R/R FL **BGB-3111-LTE1 Zanubrutinib BTKi** B-cell malignancies	**BGB-3111-206 Zanubrutinib BTKi** R/R MCL **BGB-3111-212 Zanubrutinib BTKi** R/R FL **BGB-3111-214 Zanubrutinib BTKi** R/R MZL **BGB-3111-302 Zanubrutinib BTKi** TN WM **BGB-3111-304 Zanubrutinib BTKi** TN CLL/SLL **BGB-3111-305 Zanubrutinib BTKi** R/R CLL/SLL
I&I			**BGB-3111-309 Zanubrutinib BTKi** PMN	

Refer to Glossary abbreviations

BeiGene → BeOne

Trial detail

- **BRUKINSA®** (zanubrutinib)
- **Sonrotoclax**
- **BGB-16673 BTK CDAC**
- **TEVIMBRA®** (tislelizumab)
- **Other Hematology Assets**
- **Other Solid Tumor Assets**
- **Immunology and Inflammation Assets**

BRUKINSA®
Foundational asset in hematology portfolio

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-3111-111	Phase 2	NCT04172246	B-Cell Malignancies	55		TEAEs and ORR	Maintenance (JP)
BGB-3111-215	Phase 2	NCT04116437	Previous BTKi Tx - ibru/acala intolerant	90		TEAEs	Maintenance
BGB-3111-218	Phase 2	NCT05068440	CD79b R/R DLBCL	66		ORR	Maintenance
BGB-3111-304	Phase 3	NCT03336333	TN CLL/SLL	590	Venetoclax	PFS	Maintenance
BGB-3111-306	Phase 3	NCT04002297	TN MCL	510	Rituximab	PFS	Maintenance
BGB-3111-308	Phase 3	NCT05100862	R/R MZL and FL	750	Rituximab, Obinutuzumab	PFS	Enrolling
BGB-3111-LTE1	Phase 3	NCT04170283	B-Cell Malignancies	500	Tislelizumab	TEAEs	Enrolling
BGB-3111-206	Phase 2	NCT03206970	R/R MCL	86		ORR	Approved
BGB-3111-212	Phase 2	NCT03332017	R/R NHL - FL	217	Obinutuzumab	ORR	Approved
BGB-3111-214	Phase 2	NCT03846427	R/R MZL	68		ORR	Approved
BGB-3111-302	Phase 3	NCT03053440	TN & R/R WM	201		CR\VGPR	Approved
BGB-3111-305	Phase 3	NCT03734016	R/R CLL	652		ORR	Approved

Brukinsa® zanubrutinib

Refer to Glossary abbreviations

Sonrotoclax

Potential best-in-class BCL2 inhibitor with differentiated profile

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-11417-101	**Phase 1**	NCT04277637	B-Cell Malignancies	437	Zanubrutinib, Obinutuzumab	TEAEs, MTD	Maintenance
BGB-11417-102	**Phase 1**	NCT04883957	B-Cell Malignancies	64		TEAEs, MTD	Maint. (CN)
BGB-11417-103	**Phase 1**	NCT04771130	AML/MDS	260	Azacitidine	TEAEs, CR, mOR	Enrolling
BGB-11417-105	**Phase 1**	NCT04973605	R/R MM with t(11;14)	167	Dexamethasone, Carfilzomib	TEAEs, ORR, VGPR, CR	Enrolling
BGB-11417-201	**Phase 2**	NCT05471843	Post-BTKi MCL	126		TEAEs, ORR	Maintenance
BGB-11417-202	**Phase 2**	NCT05479994	Post-BTKi CLL/SLL	100		ORR	Maintenance
BGB-11417-203	**Phase 2**	NCT05952037	R/R WM	105	Zanubrutinib	MRR	Enrolling
BGB-11417-204	**Phase 2**	NCT06637501	TN CLL	87	Zanubrutinib	CR/CRi	Enrolling
BGB-11417-301	**Phase 3**	NCT06073821	TN CLL/SLL	640	Zanubrutinib	PFS	Enrolling
BGB-11417-302	**Phase 3**	NCT06742996	R/R MCL	300	Zanubrutinib	PFS	Start Up

Refer to Glossary abbreviations

BGB-16673 BTK CDAC

Potential first-in-class BTK degrader

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-16673-101	**Phase 1/2**	NCT05006716	B-Cell Malignancies	466		TEAEs	Enrolling
BGB-16673-102	**Phase 1**	NCT05294731	B-Cell Malignancies	127		TEAEs, RP2D, ORR	Enrolling
BGB-16673-104	**Phase 1/2**	NCT06634589	B-Cell Malignancies	170	Sonrotoclax, Zanubrutinib	DLTs, TEAEs	Enrolling

Refer to Glossary abbreviations

Phase 1 - Other Hematology Assets

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-21447-101	**Phase 1**	NCT05828589	B-cell malignancies	85		DLTs, AEs, TLS	Enrolling

Refer to Glossary abbreviations

TEVIMBRA®
Poised for global patient impact

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-310	**Phase 3**	NCT03967977	1L UBC	436	Chemotherapy	OS (ITT)	Enrolling
BGB-LC-201	**Phase 2**	NCT05635708	1L NSCLC	319	LAG3, OX40, HPK1, Chemotherapy	ORR	Maintenance
BGB-LC-202	**Phase 2**	NCT05577702	Neo/adj NSCLC	120	LAG3, Chemotherapy	MPR	Maintenance
BGB-A317-103	**Phase 1**	NCT06091943	Subcutaneous administration	69		Bioavailability and Safety	Maintenance
BGB-HNSCC-201	**Phase 2**	NCT05909904	1L HNSCC	160	LAG3, TIM3	ORR	Maintenance
BGB-A317-311	**Phase 3**	NCT03957590	Localized ESCC	366	Chemotherapy + Radiotherapy	PFS	Close-out
BGB-A317-312	**Phase 3**	NCT04005716	1L ES-SCLC	455	Chemotherapy	OS	Approved*
BGB-A317-315	**Phase 3**	NCT04379635	Neo/adj NSCLC	450	Chemotherapy	MPR, EFS	Approved*
BGB-A317-203	**Phase 2**	NCT03209973	R/R cHL	68		ORR	Approved*
BGB-A317-204	**Phase 2**	NCT04004221	2L UC	110		ORR	Approved*

TEVIMBRA (tislelizumab)

* Approved only in China
Refer to Glossary abbreviations

TEVIMBRA®
Poised for global patient impact

Trial	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-A317-208	**Phase 2**	NCT03419897	2L+ HCC	250		ORR	Approved*
BGB-A317-209	**Phase 2**	NCT03736889	Late Line MSI-H or dMMR Solid Tumors	150		ORR	Approved*
BGB-A317-301	**Phase 3**	NCT03412773	1L HCC	680		OS	Approved*
BGB-A317-302	**Phase 3**	NCT03430843	2L ESCC	489		OS	Approved
BGB-A317-303	**Phase 3**	NCT03358875	2/3L NSCLC	805		OS (PDL1+), OS	Approved
BGB-A317-304	**Phase 3**	NCT03663205	1L Non-sq. NSCLC	334	Chemotherapy	PFS	Approved
BGB-A317-305	**Phase 3**	NCT03777657	1L GC	978	Chemotherapy	OS	Approved
BGB-A317-306	**Phase 3**	NCT03783442	1L ESCC	650	Chemotherapy	OS	Approved
BGB-A317-307	**Phase 3**	NCT03594747	1L Sq. NSCLC	342	Chemotherapy	PFS	Approved
BGB-A317-309	**Phase 3**	NCT03924986	1L NPC	263	Chemotherapy	PFS	Approved*

TEVIMBRA (tislelizumab)

* Approved only in China
Refer to Glossary abbreviations

Phase 1 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-290-102	Pamiparib	PARPi	Ph1	NCT03333915	Ovarian and breast cancer	128		TEAE, SAE, ORR	Approved
AMG509 20180146	Xaluritamig	STEAP1xCD3	Ph1	NCT04221542	mCRPC	9 (CN)		TEAE, DLTs	Enrolling
BGB-24714-101	BGB-24714	SMAC	Ph1	NCT05381909	Solid Tumors	229	Chemotherapy	AE, TEAE, SAE, DLT, MTD, RDFE, ORR	Expansion
BGB-A317-15025-101	BGB-15025	HPK1	Ph1	NCT04649385	Solid Tumors	169	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Maintenance
BGB-A317-30813-101	BGB-30813	DGKζ	Ph1	NCT05904496	Solid Tumors	81	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-A317-A3055-101	BGB-A3055	CCR8	Ph1	NCT05935098	Solid Tumors	89	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-C9074-101	BGB-C9074	B7H4 ADC	Ph1	NCT06233942	Solid Tumors	89	Tislelizumab	TEAE, SAE, DLT, MTD, RDFE, ORR, RP2D	Dose escalation
BG-68501-101	BG-68501	CDK2i	Ph1	NCT06257264	Solid Tumors	108	BGB-43395, Fulvestrant	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-C354-101	BGB-C354	B7H3 ADC	Ph1	NCT06422520	Solid Tumors	85	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-B2033-101	BGB-B2033	GPC3x4-1BB	Ph1	NCT06427941	Solid Tumors	140	Tislelizumab	AE, SAE, DLT, MTD, RP2D	Dose escalation
BGB-B3227-101	BGB-B3227	MUC1xCD16A	Ph1	NCT06540066	Solid Tumors	75	Tislelizumab, Chemotherapy	AE, SAE, DLT, MTD, RDFE	Dose escalation

Refer to Glossary abbreviations

Phase 1 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-43395-101	BGB-43395	CDK4i	Ph1	NCT06120283	Solid Tumors	225	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-43395-102	BGB-43395	CDK4i	Ph1	NCT06253195	Solid Tumors	78	Fulvestrant, Letrozole	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-A317-26808-101	BGB-26808	HPK1 2G	Ph1	NCT05981703	Solid Tumors	90	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BGB-R046-101	BGB-R046	IL-15 prodrug	Ph1	NCT06487858	Solid Tumors	74 (CN)	Tislelizumab	AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-C477-101	BG-C477	CEA ADC	Ph1	NCT06596473	Solid Tumors	21	Chemotherapy	AE, SAE, DLT, MTD, RDFE, ORR	Dose escalation
BG-T187-101	BG-T187	EGFRxMET Tsp	Ph1	NCT06598800	Solid Tumors	87		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BG-60366-101	BG-60366	EGFR CDAC	Ph1	NCT06685718	Solid Tumors	93		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
SHY2039-001	BG-89894	MAT2Ai	Ph1	NCT06568614	Solid Tumors	60		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation (CN)
BG-C137-101	BG-C137	FGFR2B ADC	Ph1	NCT06625593	Solid Tumors	68		AE, SAE, DLT, MTD, RDFE, ORR	Dose Escalation
BGB-53038-101	BGB-53038	Pan-KRASi	Ph1	NCT06585488	Solid Tumors	177	Tislelizumab Cetuximab	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-58067-101	BGB-58067	PRMT5i	Ph1	NCT06589596	Solid Tumors	92		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-21447-102	BGB-21447	BCL2i	Ph1	NCT06756932	2L+HR+HER2- BC	92	Fulvestrant ± BGB-43395	AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Dose Escalation
BGB-B455-101	BGB-B455	Claudin6xCD3	Ph1	NCT06803680†	Solid Tumors	80		AE, SAE, DLT, MTD, RDFE, RP2D, ORR	Not yet recruiting
AMG757 20230298	Tarlatamab	DLL3xCD3 (Subq)	Ph1	NCT06598306	2L+SCLC	10 (CN)		DLTs, TEAEs	Not yet recruiting (CN)

Refer to Glossary abbreviations

† Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

Phase 2 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20230273	Tarlatamab	DLL3xCD3	Ph2	NCT06502977	3L+ SCLC	30 (CN)		ORR	Enrolling
BGB-A317-A445-201	BGB-A445	OX40	Ph2	NCT05661955	Melanoma, UC	191	Tislelizumab	ORR	Enrolling
BGB-LBL-007-201	BGB-LBL-007	LAG3	Ph2	NCT05609370	MSS-CRC	226	Tislelizumab, Chemotherapy, Bevacizumab	PFS, AE, SAE	Close-out
BGB-LBL-007-202	BGB-LBL-007	LAG3	Ph2	NCT06010303	1L ESCC	120	Tislelizumab, Chemotherapy	ORR	Close-out

Refer to Glossary abbreviations

Phase 3 - Other Solid Tumor Assets

Trial	Asset	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
AMG757 20200041	Tarlatamab	DLL3xCD3	Ph3	NCT06211036	ES-SCLC	95 (CN)	Durvalumab	OS	Enrolling
AMG757 20230016	Tarlatamab	DLL3xCD3	Ph3	NCT06117774	LS-SCLC	77 (CN)		PFS	Enrolling
BGB-A317-290-LTE1	BeiGene assets	Multiple	Ph3	NCT04164199	Multiple	372[#]	Multiple	Immune mediated adverse events	Enrolling
ZWI-ZW25-301	Zanidatamab	HER2	Ph3	NCT05152147	1L HER2+ GEA	459	Tislelizumab ± Chemotherapy	PFS, OS	Enrolling*
AdvanTIG-302	Ociperlimab	TIGIT	Ph3	NCT04746924	1L NSCLC (PDL1 H)	671	Tislelizumab	OS	Maintenance
AMG757 20210004	Tarlatamab	DLL3xCD3	Ph3	NCT05740566	2L SCLC	98 (CN)		OS	Maintenance
BGB-290-302	Pamiparib	PARPi	Ph3	NCT03519230	Platinum-sensitive Recurrent OC	216		PFS	Maintenance

- * Enrolling completed in BeiGene Territories
- [#]Currently enrolled patients, more patients may be enrolled in future
- Refer to Glossary abbreviations

Immunology and Inflammation Assets

Trial	MOA	Phase	CT.gov	Population	Total Patients	Combination Molecule(s)	Primary Endpoint(s)	Status
BGB-3111-309	BTKi	Ph3	NCT05707377	Primary Membranous Nephropathy	283		Urine Protein Creatinine Ratio, Complete Remission	Enrolling
BGB-45035-101	IRAK4 CDAC	Ph1	NCT06342713	Healthy volunteers	195		Adverse Events Cardiac Telemetry Vital signs	Enrolling

Refer to Glossary abbreviations

Full List of Commercial and Clinical Assets

Commercial

Product	Commercial Rights	Partner
BRUKINSA® (zanubrutinib)	Global	-
TEVIMBRA® (tislelizumab)	Global	-
PARTRUVIX® (pamiparib)	Global	-
IMDELLTRA® (tarlatamab)[1]	China	Amgen
XGEVA® (denosumab)	China	Amgen
BLINCYTO® (blinatumomab)	China	Amgen
KYPROLIS® (carfilzomib)	China	Amgen
SYLVANT® (siltuximab)	China	EUSA Pharma
QARZIBA® (dinutuximab)	China	EUSA Pharma
POBEVCY® (Avastin biosimilar)	China	Bio-Thera
BAITUOWEI® (goserelin microspheres for injection)	China	Luye Pharma
TAFINLAR® (dabrafenib)	China	Novartis
MEKINIST® (trametinib)	China	Novartis
VOTRIENT® (pazopanib)	China	Novartis
AFINITOR® (everolimus)	China	Novartis
ZYKADIA® (ceritinib)	China	Novartis

Pipeline

Asset	Latest Stage	Partner	Asset	Latest Stage	Partner
Sonrotoclax (BCL2i)	Ph3	-	**Xaluritamig (STEAP1xCD3 XmAb®)***	Ph1	Amgen
Ociperlimab (TIGIT mAb)	Ph3	-	**BGB-45035 (IRAK4 CDAC)**	Ph1	-
Zanidatamab (HER2 BsAb)	Ph3	Zymeworks/Jazz	**BGB-C354 (B7H3 ADC)**	Ph1	-
Tarlatamab (DLL3xCD3 BiTE®)*	Ph3	Amgen	**BGB-R046 (IL-15 prodrug)**	Ph1	-
BGB-16673 (BTK CDAC)	Ph2	-	**BGB-B2033 (GPC3x4-1BB BsAb)**	Ph1	-
-007 (LAG-3)	Ph2	Leads Biolabs	**BGB-3227 (MUC1xCD16A BsAb)**	Ph1	-
BGB-A445 (OX40)	Ph2	-	**BG-T187 (EGFRxMET TsAb)**	Ph1	-
BGB-21447 (BCL2i 2G)	Ph1	-	**BG-C137 (FGFR2b ADC)**	Ph1	-
BGB-15025 (HPK1i)	Ph1	-	**BGB-53038 (PanKRASi)**	Ph1	-
BGB-26808 (HPK1i 2G)	Ph1	-	**BG-58067 (MTA Coop PRMT5i)**	Ph1	-
BGB-30813 (DGKζi)	Ph1	-	**BG-C477 (CEA ADC)**	Ph1	-
BGB-A3055 (CCR8 mAb)	Ph1	-	**BG-89894 (MAT2Ai)**	Ph1	CSPC
BGB-24714 (SMAC mimetic)	Ph1	-			
BGB-43395 (CDK4i)	Ph1	-			
BG-60366 (EGFR CDAC)	Ph1	-			
BGB-B455 (CLDN6 x CD3 BsAb)†	Ph1	-			
BGB-68501 (CDK2i)	Ph1	Ensem			
BG-C9074 (B7H4 ADC)	Ph1	Duality Bio			

† Trial is listed on clinicaltrials.gov, but may not have subjects enrolled

[1]Amgen collaboration. BeiGene has tiered mid-single digit royalties on net sales

* Study is being conducted in China as part of the BeiGene-Amgen collaboration

BeiGene holds commercial rights in China for REVLIMID® (lenalidomide) and VIDAZA® (azacitidine) through its BMS partnership until February 28, 2025

Glossary

Disease abbreviations

AML	Acute myeloid leukemia
BiTE	Bi-specific T-cell engager
BP-ALL	B-precursor acute lymphocytic leukemia
BTC	Biliary tract cancer
CHL	Classic Hodgkin's lymphoma
CLL	Chronic lymphocytic leukemia
dMMR	Deficient DNA mismatch repair
DLBCL	Diffuse large B-cell lymphoma
ES-SCLC	Extensive stage small cell lung cancer
ESCC	Esophageal squamous cell carcinoma
FL	Follicular lymphoma
GEA	Gastroesophageal adenocarcinoma
GC	Gastric cancer
HCC	Hepatocellular cancer
HNSCC	Head and neck squamous cell carcinoma
LS-SCLC	Limited stage small cell lung cancer
MCL	Mantle cell lymphoma
mCRPC	Metastatic castration resistant prostate cancer
MDS	Myelodysplastic syndromes
MM	Multiple myeloma
MSI-H	Microsatellite stability high
MSS CRC	Microsatellite stable colorectal cancer
MZL	Marginal zone lymphoma
Neo/adj	Neoadjuvant/adjuvant
NSCLC	Non-small cell lung cancer
NPC	Nasopharyngeal carcinoma
OC	Ovarian cancer
PMN	Primary membranous nephropathy
R/R	Relapsed or refractory
SCLC	Small cell lung cancer
SLL	Small lymphocytic lymphoma
UC / UBC	Urinary / bladder cancer
WM	Waldenström's macroglobulinemia

Other abbreviations

ADC	Antibody drug conjugate	**MTx**	Maintenance
AE	Adverse event	**ORR**	Objective response rate
BiTE®	Bi-specific T-cell engager	**OS**	Overall survival
CDAC	Chimeric degradation activation compound	**PCR**	Pathologic complete response
CR	Complete response	**PFS**	Progression-free survival
DCR	Disease control rate	**RDFE**	Recommended dose for expansion
DLT	Dose-limiting toxicity	**RP2D**	Recommended phase 2 dose
DOR	Duration of response	**SAE**	Severe adverse event
EFS	Event free survival	**TEAE**	Treatment emergent adverse event
LCM	Lifecycle management	**TN**	Treatment naïve
LTE	Long-term extension	**Tsp**	Tri-specific antibody
mAb	Monoclonal antibody	**VGPR**	Very good partial response
mOR	Modified overall response	**XmAb®**	XmAb is a registered trademark of Xencor, Inc.
MPR	Major pathological response		
MTD	Maximum tolerated dose		


BeiGene
BeOne